formaldehyde has been researched along with pioglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghorbanzadeh, B; Mansouri, MT; Naghizadeh, B; Pashmforoush, M; Rajabi, H | 1 |
| Alavi, K; Dwyer-Nield, LD; Ghosh, M; Hudish, LI; Hudish, TM; Keith, RL; McArthur, DG; Merrick, DT; Mirita, C; Smith, AJ; Sompel, K; Tennis, MA | 1 |
2 other study(ies) available for formaldehyde and pioglitazone
| Article | Year |
|---|---|
Pharmacological evidence for systemic and peripheral antinociceptive activities of pioglitazone in the rat formalin test: Role of PPARĪ³ and nitric oxide.
Topics: Analgesics; Anilides; Animals; Drug Interactions; Formaldehyde; Locomotion; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Thiazolidinediones | 2017 |
PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Desmoglein 3; Epithelial-Mesenchymal Transition; Female; Formaldehyde; Humans; Keratin-5; Lung; Lung Neoplasms; Mice; Pioglitazone; PPAR gamma; RNA, Messenger; Tubulin | 2022 |